LPL Financial’s Atara Biotherapeutics ATRA Stock Holding History

LPL Financial’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-405	Closed	-$181K	–	4348
2021 Q3	$181K	Buy	+405	New	+$145K	﹤0.01%	4019

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

LPL Financial's ATRA Position: Q4 2021 in Review

LPL Financial sold out of Atara Biotherapeutics (ATRA) in Q4 2021, closing a stake of 405 shares — an estimated $181K sold.

LPL Financial first reported a position in ATRA in Q3 2021 and held it in 1 quarter. The position peaked at $181K in Q3 2021. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2021.

LPL Financial reported no remaining Atara Biotherapeutics position as of Q4 2021 after selling out during the quarter.
LPL Financial sold 405 Atara Biotherapeutics shares in Q4 2021, an estimated $181K.
LPL Financial first reported a position in Atara Biotherapeutics in Q3 2021 and held it in 1 quarter.
LPL Financial's Atara Biotherapeutics position peaked at $181K in Q3 2021.
139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2021.

Based on LPL Financial's 13F filing for Q4 2021, filed 14 Feb 2022.